The US Congressional committee, which is inquiring into the country's Food and Drug Administration's handling of drug-marketing approvals of India's leading drug-maker Ranbaxy, has extended its probe into similar permissions given to Iceland's Actavis.
Having made no headway to amend a 26-year-old double taxation avoidance agreement with Mauritius, the finance ministry has hardened its stance against broadening India's economic engagement with the island nation.
In a move aimed at encouraging the growth of innovation-driven industries, the Ministry of Science and Technology has proposed to set up special innovation zones that will offer a host of fiscal incentives for research and development companies in India.
The World Health Organization has given five more months to the Drugs Controller General of India to upgrade its performance to international standards. The extension of the current deadline of October-end came after a visiting WHO team found the modernisation programmes of the Indian drug regulator on track.
In effect, the government proposes to relax the norms with regard to foreign participation in multi-brand retail by opening up these specialised sectors, while keeping grocery and consumer goods retail out of bounds. The move comes months after the Left parties, which were opposed to any relaxation of FDI norms for the retail sector, pulled out of the United Progressive Alliance government.
Sun generates 41 per cent of its annual revenues from the US market, a record of sorts among Indian drug firms. The company is bullish on its US prospects and expects 25 per cent growth in the country this year, higher than the 18-20 per cent growth projection it has given for other markets including India. The US is the world's largest market for medicines and accounts for nearly 50 per cent of the $780 billion global medicine sales.
Move to make investing in sectors with FDI cap easier.
The first petition alleges that Cipla Ltd, India's second largest pharmaceutical company, violated Roche's patent by launching a generic version of Valcyte. The second petition says Cipla violated the Swiss drug maker's trademark by launching the product in a phonetically similar name, 'Valcept'.
The relaxation will apply to those sectors that have composite caps (foreign direct investment or FDI plus FII). "The move will not impact sectors like banking and insurance which are governed by Acts of Parliament. However, sectors with composite caps which see administrative control like telecommunication services, broadcast services like direct-to-home and FM radio will benefit," a Delhi based FDI policy expert told Business Standard.
Mobile telecom service providers are up against a new problem -- unidentified operators have been found to take out subsidised handsets from their 'bundled' connections and ship them to overseas markets at significantly higher prices.
The government may liberalise external commercial borrowing rules in the next few days, especially for the infrastructure sector including capital-intensive ones like telecom, a Finance Ministry official said on Friday.
The group's testing lab chain SRL Ranbaxy has been renamed as Religare Super Laboratories. RanAir, its charter aviation company will be known as Religare Voyages. About 15 group companies, including joint ventures like Religare Macquarie Private Wealth, Religare Aegon and Vistaar Religare have come under the umbrella brand Religare.
Companies like Shanta Biotech, Panacea Biotec and Serum Institute of India are among the leading vaccine makers which have not been able to file any fresh application to the WHO due to this temporary de-recognition of the country's drug regulatory system. The WHO pre-qualification is essential for companies to supply vaccines to national immunisation programmes funded by the WHO or UNICEF outside the country.
Hospitals and medical research organisations that conduct clinical trials on humans may soon face surprise inspections from the regulatory authorities. The hospitals, the sponsor pharma companies and the institutional ethics committees that oversee these trials will all come under the regulator's scanner.
More than nuclear power, India stands to gain access to a wide range of dual-use goods and technologies, from which it was barred, as a result of the waiver by the 45-country Nuclear Suppliers' Group.
It has been nearly four months since Sidharth Punshi, 34, former executive director at Goldman Sachs, joined Jefferies International, a global investment bank and institutional securities firm, as the managing director and country head for India. In a recent interview, Punshi told Business Standard that despite the tight liquidity scenario and a challenging global situation, Indian companies continue to chase merger and acquisition deals abroad.
Data on clinical trials of genetically-modified brinjal have been made public by the Genetic Engineering Approval Committee of the environment ministry.
Promoters of Rajasthan Royals look to spin off team's success for better valuations.
The WHO feels that the practice is not only against international ethics, but also increases the risk of wrong medication. INNs are names that help to identify the chemical composition of a pharmaceutical substance without having to use long and unwieldy chemical names.
Several Indian states including Himachal Pradesh, Delhi, Goa, Madhya Pradesh and Bihar are offering their hospitals to the private sector to manage. This has elicited immediate positive reactions from private sector hospital chains - among them Fortis Healthcare, Apollo Hospitals and Wockhardt Hospitals.
© 2025 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances